New Haven, CTNCT06393738Now EnrollingIRB Ready

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) Clinical Trial in New Haven, CT

Access cutting-edge relapsed/refractory (r/r) mature b cell non hodgkin lymphoma (nhl) treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.

Sponsored by Arvinas Inc.

Quick Self-Assessment

See if you qualify for this New Haven location

Preparing your pre-screening questions…

Expert Care in New Haven

Access relapsed/refractory (r/r) mature b cell non hodgkin lymphoma (nhl) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related relapsed/refractory (r/r) mature b cell non hodgkin lymphoma (nhl) treatment provided free

Apply for This New Haven Location

Check if you qualify for this relapsed/refractory (r/r) mature b cell non hodgkin lymphoma (nhl) clinical trial in New Haven, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Haven

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Haven site if eligible
  4. 4Begin participation

About This Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) Study in New Haven

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.

Sponsor: Arvinas Inc.

Who Can Participate

Inclusion Criteria

For Part A and B: Have relapsed/refractory NHL and \>=2 prior systemic therapies, (including rituximab), and be ineligible for known therapies with demonstrated clinical benefit per investigator assessment or, histologically confirmed AITL that has recurred or progressed following institutional standard of care therapy.
For Part C and D: Have R/R DLBCL, not otherwise specified \[NOS (DLBCL, NOS)\] or large B-cell lymphoma (LBCL) arising from follicular lymphoma and have received two or more lines of systemic therapy.
Have at least one bi dimensionally measurable lesion \>1.5-centimeter (cm) in largest dimension for nodal or \>1.0 cm for extranodal lesion.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (NOTE: For Part A only - ECOG PS of 2 is allowed for participants with secondary CNS lymphoma).
Adequate bone marrow function
Adequate kidney function
Adequate Liver Function

Exclusion Criteria

Current or past history of peripheral eosinophilia, hypereosinophilic syndrome (HES), organ-specific eosinophilic disorder, or drug reaction with eosinophilia and systemic symptoms (DRESS).
Prior allogeneic stem cell transplant (SCT) or solid organ transplantation.
Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, melanoma in situ or carcinoma in situ of the breast or cervix, and prostate cancer with active surveillance.
Any of the following in the previous 6 months:
Myocardial infarction, long QT syndrome or family history of long QT syndrome, or Torsade de Pointes;
Clinically important atrial or ventricular arrhythmias;
Serious conduction system abnormalities, 3rd degree atrioventricular (AV block), unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (CHF), New York Heart Association Class III or IV;
Cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism, and/or other clinically significant episode of thromboembolic disease;
Active inflammatory gastrointestinal (GI) disease, chronic diarrhea, previous gastric resection, or lap band surgery.
Uncontrolled hypertension despite optimal medical treatment
History of myocarditis.
In ability to comply with listed prohibited treatments.
Standard 12-lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
Cardiac ejection fraction \<45%.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Haven?

Yes, this clinical trial (NCT06393738) has an active research site in New Haven, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) Treatment Options in New Haven, CT

If you're searching for relapsed/refractory (r/r) mature b cell non hodgkin lymphoma (nhl) treatment options in New Haven, CT, this clinical trial (NCT06393738) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced relapsed/refractory (r/r) mature b cell non hodgkin lymphoma (nhl) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all relapsed/refractory (r/r) mature b cell non hodgkin lymphoma (nhl) clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in New Haven, CT

See all lymphoma clinical trials recruiting in New Haven — not just this study.

Browse Lymphoma Trials in New Haven →

Browse More Trials by Condition

Lymphoma TrialsRheumatoid Arthritis TrialsAntiphospholipid Syndrome TrialsPulmonary Hypertension TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in New Haven?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Haven, CT